Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05014919 · ClinicalTrials.gov registry record · Phase 3
Vortioxetine to Prevent Return of Symptoms in Children With Depression
A Phase 3 study, sponsored by H. Lundbeck A/S.
- Terminated
- Registry status
- Phase 3
- Development phase
- 35
- Enrollment target
NCT05014919 is a Phase 3 study that was terminated before completion, run by H. Lundbeck A/S. The registered enrollment target is 35 participants.
The verdict
NCT05014919, a Phase 3 study, was terminated before completion, sponsored by H. Lundbeck A/S.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if vortioxetine is better than placebo (sugar pills) in preventing depression in children who improved when treated with vortioxetine.
Interventions
- DRUG Placebo
- DRUG Vortioxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2021-08-10 |
| Est. Completion | 2022-04-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05014919
The ClinicalTrials.gov registry entry for NCT05014919 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05014919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05014919 about?
NCT05014919 is a clinical study titled "Vortioxetine to Prevent Return of Symptoms in Children With Depression". The purpose of this study is to find out if vortioxetine is better than placebo (sugar pills) in preventing depression in children who improved when treated with vortioxetine.
What is the current status of trial NCT05014919?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 35 participants. The study started on 2021-08-10. Estimated completion is 2022-04-28.
What interventions are being tested in trial NCT05014919?
The interventions under investigation include: Placebo (DRUG), Vortioxetine (DRUG).
Who is sponsoring clinical trial NCT05014919?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.